NexImmune and ASLAN Pharmaceuticals Compared in Financial Analysis

Comparing revenue, earnings, valuation, and other key metrics between the two biotech companies.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

This article provides a financial analysis comparing NexImmune (OTCMKTS:NEXI) and ASLAN Pharmaceuticals (NASDAQ:ASLN). The analysis looks at metrics like revenue, earnings per share (EPS), valuation, institutional ownership, and stock volatility. NexImmune has higher earnings but lower revenue than ASLAN Pharmaceuticals, and ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio.

Why it matters

This comparison of the two biotech companies provides investors with valuable insights to help them evaluate the relative financial performance and investment potential of NexImmune and ASLAN Pharmaceuticals. Understanding the key differences in metrics like valuation, earnings, and institutional ownership can inform investment decisions in the competitive biotech sector.

The details

NexImmune has higher earnings per share (EPS) than ASLAN Pharmaceuticals, but ASLAN Pharmaceuticals has higher revenue. ASLAN Pharmaceuticals is trading at a lower price-to-earnings (P/E) ratio, indicating it may be more affordable than NexImmune. ASLAN Pharmaceuticals also has stronger institutional ownership, with 58.8% of shares held by institutions compared to only 9.9% for NexImmune. However, NexImmune has higher insider ownership at 14.9% versus 4.7% for ASLAN Pharmaceuticals. NexImmune also has a much lower beta of -2289.14, meaning its stock is significantly less volatile than the overall market, while ASLAN Pharmaceuticals has a beta of 1.4, making it 40% more volatile than the S&P 500.

  • The financial data in this analysis is current as of February 27, 2026.

The players

NexImmune, Inc.

A clinical-stage biotechnology company developing T cell immunotherapies for cancer and other immune-mediated diseases, headquartered in Gaithersburg, Maryland.

ASLAN Pharmaceuticals Limited

A clinical-stage biopharmaceutical company focused on immunology, headquartered in Singapore and developing treatments for atopic dermatitis and other autoimmune conditions.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key financial differences between NexImmune and ASLAN Pharmaceuticals, providing investors with important metrics to consider when evaluating the two biotech companies. The data suggests ASLAN Pharmaceuticals may be more affordable based on valuation, but NexImmune has stronger insider ownership and lower stock volatility.